Compare DARE & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DARE | NEPH |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4M | 40.1M |
| IPO Year | 2014 | 2004 |
| Metric | DARE | NEPH |
|---|---|---|
| Price | $2.08 | $3.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.00 | $6.00 |
| AVG Volume (30 Days) | ★ 147.6K | 9.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | $2,807,885.00 | ★ $18,789,000.00 |
| Revenue This Year | $2,115.12 | $11.24 |
| Revenue Next Year | $122.62 | $11.58 |
| P/E Ratio | ★ N/A | $340.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $1.27 | $2.66 |
| 52 Week High | $9.19 | $6.42 |
| Indicator | DARE | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 52.99 |
| Support Level | $1.95 | $2.77 |
| Resistance Level | $2.23 | $3.79 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 54.17 | 56.15 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.